Pre-Market Approval by FDA for NeuroPace RNS Stimulator

by Savitha C Muppala on  November 19, 2013 at 9:43 AM Medical Gadgets   - G J E 4
StimulatorNeuroPace has received the pre-market nod by FDA for the NeuroPace RNS System, employed in the treatment of medically refractory partial epilepsy.
 Pre-Market Approval by FDA for NeuroPace RNS Stimulator
Pre-Market Approval by FDA for NeuroPace RNS Stimulator

Electrical activity in the brain is monitored by the battery powered device which is implanted in the cranium. If any abnormal activity is detected, electrical impulses are sent to the seizure focus in the brain via leads, and this assists in preventing the onset of a seizure.

The RNS System also comprises of a programmer for physicians where they can program the detection and stimulation parameters for the implanted device non-invasively. They can also take a look at the patients' electrocorticogram (ECoG) in real time and upload previously recorded ECoGs stored on the RNS implant.

Results have pointed to benefits to the tune of a 37.9% reduction in seizure frequency for subjects with active implants. More than 50% of people experienced a reduction in seizures of 50% or more.

"The RNS System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than two epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures."

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like